246 related articles for article (PubMed ID: 16034464)
21. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
Okamoto M; Hayakawa F; Miyata Y; Watamoto K; Emi N; Abe A; Kiyoi H; Towatari M; Naoe T
Leukemia; 2007 Mar; 21(3):403-10. PubMed ID: 17230226
[TBL] [Abstract][Full Text] [Related]
22. Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention.
Reikvam H; Hatfield KJ; Ersvaer E; Hovland R; Skavland J; Gjertsen BT; Petersen K; Bruserud O
Br J Haematol; 2012 Feb; 156(4):468-80. PubMed ID: 22150087
[TBL] [Abstract][Full Text] [Related]
23. Geldanamycin, a heat shock protein 90-binding agent, disrupts Stat5 activation in IL-2-stimulated cells.
Xu W; Yu F; Yan M; Lu L; Zou W; Sun L; Zheng Z; Liu X
J Cell Physiol; 2004 Feb; 198(2):188-96. PubMed ID: 14603521
[TBL] [Abstract][Full Text] [Related]
24. Flt3 mutation activates p21WAF1/CIP1 gene expression through the action of STAT5.
Takahashi S; Harigae H; Kaku M; Sasaki T; Licht JD
Biochem Biophys Res Commun; 2004 Mar; 316(1):85-92. PubMed ID: 15003515
[TBL] [Abstract][Full Text] [Related]
25. FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy.
Naoe T; Kiyoe H; Yamamoto Y; Minami Y; Yamamoto K; Ueda R; Saito H
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S27-30. PubMed ID: 11587362
[TBL] [Abstract][Full Text] [Related]
26. Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations.
Robinson LJ; Xue J; Corey SJ
Exp Hematol; 2005 Apr; 33(4):469-79. PubMed ID: 15781338
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor.
Tse KF; Novelli E; Civin CI; Bohmer FD; Small D
Leukemia; 2001 Jul; 15(7):1001-10. PubMed ID: 11455967
[TBL] [Abstract][Full Text] [Related]
28. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.
Al Shaer L; Walsby E; Gilkes A; Tonks A; Walsh V; Mills K; Burnett A; Rowntree C
Br J Haematol; 2008 May; 141(4):483-93. PubMed ID: 18373709
[TBL] [Abstract][Full Text] [Related]
29. In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor.
Zhao M; Kiyoi H; Yamamoto Y; Ito M; Towatari M; Omura S; Kitamura T; Ueda R; Saito H; Naoe T
Leukemia; 2000 Mar; 14(3):374-8. PubMed ID: 10720129
[TBL] [Abstract][Full Text] [Related]
30. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--Inhibition of P-glycoprotein function by 17-AAG.
Radujkovic A; Schad M; Topaly J; Veldwijk MR; Laufs S; Schultheis BS; Jauch A; Melo JV; Fruehauf S; Zeller WJ
Leukemia; 2005 Jul; 19(7):1198-206. PubMed ID: 15902298
[TBL] [Abstract][Full Text] [Related]
31. The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112.
Yang X; Liu L; Sternberg D; Tang L; Galinsky I; DeAngelo D; Stone R
Cancer Res; 2005 Aug; 65(16):7338-47. PubMed ID: 16103085
[TBL] [Abstract][Full Text] [Related]
32. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.
Mizuki M; Fenski R; Halfter H; Matsumura I; Schmidt R; Müller C; Grüning W; Kratz-Albers K; Serve S; Steur C; Büchner T; Kienast J; Kanakura Y; Berdel WE; Serve H
Blood; 2000 Dec; 96(12):3907-14. PubMed ID: 11090077
[TBL] [Abstract][Full Text] [Related]
33. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.
Grundler R; Thiede C; Miething C; Steudel C; Peschel C; Duyster J
Blood; 2003 Jul; 102(2):646-51. PubMed ID: 12663439
[TBL] [Abstract][Full Text] [Related]
34. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.
Rahmani M; Yu C; Dai Y; Reese E; Ahmed W; Dent P; Grant S
Cancer Res; 2003 Dec; 63(23):8420-7. PubMed ID: 14679005
[TBL] [Abstract][Full Text] [Related]
35. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.
Guo F; Rocha K; Bali P; Pranpat M; Fiskus W; Boyapalle S; Kumaraswamy S; Balasis M; Greedy B; Armitage ES; Lawrence N; Bhalla K
Cancer Res; 2005 Nov; 65(22):10536-44. PubMed ID: 16288046
[TBL] [Abstract][Full Text] [Related]
36. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.
Choudhary C; Schwäble J; Brandts C; Tickenbrock L; Sargin B; Kindler T; Fischer T; Berdel WE; Müller-Tidow C; Serve H
Blood; 2005 Jul; 106(1):265-73. PubMed ID: 15769897
[TBL] [Abstract][Full Text] [Related]
37. The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors.
Hunter HM; Pallis M; Seedhouse CH; Grundy M; Gray C; Russell NH
Br J Haematol; 2004 Oct; 127(1):26-33. PubMed ID: 15384974
[TBL] [Abstract][Full Text] [Related]
38. FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).
Bagrintseva K; Geisenhof S; Kern R; Eichenlaub S; Reindl C; Ellwart JW; Hiddemann W; Spiekermann K
Blood; 2005 May; 105(9):3679-85. PubMed ID: 15626738
[TBL] [Abstract][Full Text] [Related]
39. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.
Yu W; Rao Q; Wang M; Tian Z; Lin D; Liu X; Wang J
Leuk Res; 2006 May; 30(5):575-82. PubMed ID: 16213582
[TBL] [Abstract][Full Text] [Related]
40. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
Augustin E; Skwarska A; Weryszko A; Pelikant I; Sankowska E; Borowa-Mazgaj B
Acta Pharmacol Sin; 2015 Mar; 36(3):385-99. PubMed ID: 25640477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
